The Current Status and Potential Role of Laboratory Testing to Prevent Transfusion-Transmitted Malaria

Seed, Clive R.; Kitchen, A. D.; Davis, Timothy M. E.

doi:10.1016/j.tmrv.2005.02.004

Cited by 88 publications

(113 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…pool after a short deferral period (as is done in some countries [20,43]), could significantly increase the pool of available donors, since most deferrals are imposed on the basis of travel to low-risk areas (e.g., Mexico) and since the rate of post-transfusion-transmitted malaria (PTTM) in the United States is extremely low (28,36). However, while the rate of PTTM is low, there exists a significant percentage of nondeferred donors who harbor anti-Plasmodium antibodies.…”

Section: Discussionmentioning

confidence: 99%

Detection ofPlasmodium falciparum,P. vivax,P. ovale, andP. malariaeMerozoite Surface Protein 1-p19 Antibodies in Human Malaria Patients and Experimentally Infected Nonhuman Primates

Muerhoff

Birkenmeyer

Coffey

et al. 2010

Clin Vaccine Immunol

View full text Add to dashboard Cite

Approximately 3.2 billion people live in areas where malaria is endemic, and WHO estimates that 350 to 500 million malaria cases occur each year worldwide. This high prevalence, and the high frequency of international travel, creates significant risk for the exportation of malaria to countries where malaria is not endemic and for the introduction of malaria organisms into the blood supply. Since all four human infectious Plasmodium species have been transmitted by blood transfusion, we sought to develop an enzyme-linked immunosorbent assay (ELISA) capable of detecting antibodies elicited by infection with any of these species. The merozoite surface protein 1 (MSP1), a P. falciparum and P. vivax vaccine candidate with a well-characterized immune response, was selected for use in the assay. The MSP1 genes from P. ovale and P. malariae The commercial ELISA detected all malaria patients with P. falciparum or P. vivax infections, as did the corresponding species-specific p19 ELISAs. However, the commercial ELISA detected antibodies in 0/2 and 5/8 individuals with P. malariae and P. ovale infections, respectively, while the p19 assays detected 100% of individuals with confirmed P. malariae or P. ovale infections. In experimentally infected nonhuman primates, the use of MSP1-p19 antigens from all four species resulted in the detection of antibodies within 2 to 10 weeks postinfection. Use of MSP1-p19 antigens from all four Plasmodium species in a single immunoassay would provide significantly improved efficacy compared to existing tests.

show abstract

Section: Discussionmentioning

confidence: 99%

Detection ofPlasmodium falciparum,P. vivax,P. ovale, andP. malariaeMerozoite Surface Protein 1-p19 Antibodies in Human Malaria Patients and Experimentally Infected Nonhuman Primates

Muerhoff

Birkenmeyer

Coffey

et al. 2010

Clin Vaccine Immunol

View full text Add to dashboard Cite

show abstract

“…For malaria detection, high-throughput detection cannot be achieved with microscopy of Giemsa-stained thick and thin smears or readily with individually packaged MRDTs (46). Current antigen detection and nucleic acid amplification methods have too high of thresholds of detection to detect individuals with very low parasitemias (84). Plate enzyme immunoassay technology for detection of malaria antibodies has shown the most promise for this purpose (46,47).…”

Section: Diagnosis Of Falciparum Malaria Remote From Acute Infectionmentioning

confidence: 99%

Update on Rapid Diagnostic Testing for Malaria

et al. 2008

View full text Add to dashboard Cite

SUMMARY To help mitigate the expanding global impact of malaria, with its associated increasing drug resistance, implementation of prompt and accurate diagnosis is needed. Malaria is diagnosed predominantly by using clinical criteria, with microscopy as the current gold standard for detecting parasitemia, even though it is clearly inadequate in many health care settings. Rapid diagnostic tests (RDTs) have been recognized as an ideal method for diagnosing infectious diseases, including malaria, in recent years. There have been a number of RDTs developed and evaluated widely for malaria diagnosis, but a number of issues related to these products have arisen. This review highlights RDTs, including challenges in assessing their performance, internationally available RDTs, their effectiveness in various health care settings, and the selection of RDTs for different health care systems.

show abstract

“…In an Australia study detecting antibodies by ELISA, Seed et al (2005) found that a targeted screening strategy, combined with a sensitive antibody screening test, increased the efficacy of screening when used in a four-month cellular component restriction period for donors with a declared malarial risk.…”

Section: Discussionmentioning

confidence: 99%

Malaria seroprevalence in blood bank donors from endemic and non-endemic areas of Venezuela

Contreras

Donato

Rivas

et al. 2011

Mem. Inst. Oswaldo Cruz

View full text Add to dashboard Cite

show abstract

The Current Status and Potential Role of Laboratory Testing to Prevent Transfusion-Transmitted Malaria

Cited by 88 publications

References 38 publications

Detection ofPlasmodium falciparum,P. vivax,P. ovale, andP. malariaeMerozoite Surface Protein 1-p19 Antibodies in Human Malaria Patients and Experimentally Infected Nonhuman Primates

Detection ofPlasmodium falciparum,P. vivax,P. ovale, andP. malariaeMerozoite Surface Protein 1-p19 Antibodies in Human Malaria Patients and Experimentally Infected Nonhuman Primates

Update on Rapid Diagnostic Testing for Malaria

Malaria seroprevalence in blood bank donors from endemic and non-endemic areas of Venezuela

Contact Info

Product

Resources

About